Cargando…

Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers

Detalles Bibliográficos
Autores principales:	Gschwantler-Kaulich, Daphne, Weingartshofer, Sigrid, Rappaport-Fürhauser, Christine, Zeillinger, Robert, Pils, Dietmar, Muhr, Daniela, Braicu, Elena I., Kastner, Marie-Therese, Tan, Yen Y., Semmler, Lorenz, Sehouli, Jalid, Singer, Christian F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903593/ https://www.ncbi.nlm.nih.gov/pubmed/29664962 http://dx.doi.org/10.1371/journal.pone.0196142

Ejemplares similares

Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2017)

Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers
por: Rieder, Viktoria, et al.
Publicado: (2015)

Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer
por: Danzinger, Sabine, et al.
Publicado: (2019)

Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients
por: Singer, Christian F., et al.
Publicado: (2019)

Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2017)

CA125 Levels in BRCA mutation carriers – a retrospective single center cohort study
por: Gebhart, P, et al.
Publicado: (2023)

HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2016)

Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer
por: Svoboda, Martin, et al.
Publicado: (2018)

Patient satisfaction after breast cancer surgery: A prospective clinical trial
por: Leser, Carmen, et al.
Publicado: (2020)

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2014)

Cadherin-11 expression is upregulated in invasive human breast cancer
por: Pohlodek, Kamil, et al.
Publicado: (2016)

Fertility-Sparing Surgery in Early Epithelial Ovarian Cancer: A Viable Option?
por: Fotopoulou, Christina, et al.
Publicado: (2012)

A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium
por: Pils, Dietmar, et al.
Publicado: (2013)

AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer
por: Svoboda, Martin, et al.
Publicado: (2016)

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2013)

Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer
por: Mungenast, Felicitas, et al.
Publicado: (2017)

Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer
por: Dědová, Tereza, et al.
Publicado: (2019)

Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer
por: Meshcheryakova, Anastasia, et al.
Publicado: (2019)

The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases
por: Biskup, Karina, et al.
Publicado: (2014)

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2012)

Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer
por: Biskup, Karina, et al.
Publicado: (2021)

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations
por: Reichl, Florian, et al.
Publicado: (2021)

Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2020)

Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study
por: Watrowski, Rafał, et al.
Publicado: (2022)

In Situ N-Glycosylation Signatures of Epithelial Ovarian Cancer Tissue as Defined by MALDI Mass Spectrometry Imaging
por: Grzeski, Marta, et al.
Publicado: (2022)

Altered Expression of RB and pRB in Tissue Arrays of Primary Breast Cancers and Matched Axillary Lymph Node Metastases
por: Leser, Carmen, et al.
Publicado: (2022)

Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
por: Baum, Joanna, et al.
Publicado: (2023)

Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis
por: Cherif, Soumia, et al.
Publicado: (2021)

Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy
por: Arsenic, Ruza, et al.
Publicado: (2015)

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium
por: Trillsch, Fabian, et al.
Publicado: (2013)

Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium
por: Obermayr, Eva, et al.
Publicado: (2017)

In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients
por: Kassuhn, Wanja, et al.
Publicado: (2023)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Odén, Lovisa, et al.
Publicado: (2016)

BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers
por: Semmler, Lukas, et al.
Publicado: (2019)

Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)
por: Kischkel, Frank Christian, et al.
Publicado: (2017)

Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria
por: Deutschmann, Christine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ks13jkspldg1ba7lso28m6nsou